Seeking Alpha

Shares of Gilead Sciences (GILD) soar 13.5% premarket after the firm reports positive results...

Shares of Gilead Sciences (GILD) soar 13.5% premarket after the firm reports positive results from a 12-week study of its Hepatitis C treatment GS-7977.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector